Diagnostic and Therapeutic Advances in Primary Biliary Cholangitis: Maximizing Opportunities to Improve Patient Care and Outcomes

Statement of Need

Primary biliary cholangitis (PBC) is a chronic autoimmune disease of the intrahepatic bile ducts that is often misdiagnosed until it progresses to advanced stages, including end-stage liver disease. Symptoms such as intractable pruritus and severe fatigue, often accompanied by abnormal liver function tests should elicit clinical suspicion of PBC, a so-called “common rare” disease. While PBC disproportionately affects middle-aged White women, it is increasingly being seen in men and in African American and Asian American populations. The increasing prevalence of PBC, coupled with disparities in diagnosis and treatment access, highlight the urgent need for improved clinical awareness.

In this CME Outfitters live webcast, expert faculty will assess the burden of delayed diagnosis on patients with PBC, review evidence-based strategies for early, non-invasive detection, and discuss contemporary clinical pathways for treatment, including recent FDA-approved options. The program will also emphasize interdisciplinary collaboration and shared decision-making to empower patients and improve health outcomes through informed and equitable care. Learners will be equipped with evidence-based tools to help incorporate diagnostic and treatment approaches at the point of care.

Learning Objectives

At the conclusion of this activity, learners will be able to better:

Assess the burden of delayed diagnosis on patients. Identify signs and symptoms of PBC, including pruritus, fatigue, and/or abnormal liver function tests
Implement evidence-based strategies for early and accurate diagnosis of PBC
Incorporate contemporary clinical pathways for treating PBC that consider MOA, indications, efficacy, and safety

Financial Support

Supported by an educational grant from Gilead Sciences, Inc.

Target Audience

Primary: Hepatologists, gastroenterologists

Secondary: Primary care physicians (PCPs)/OBGYNs, physician associates (PAs), nurse practitioners (NPs), registered nurses (RNs), pharmacists

Credit Information

Jointly Accredited Provider

In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physicians (ACCME) 1.0

CME Outfitters, LLC, designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacists (ACPE) 1.0

This application-based activity is approved for 1.00 contact hours (0.1 CEUs) of continuing pharmacy credit (JA0007185-0000-24-098-L01-P).

Nurses (ANCC) 1.0

This activity is designated for 1.00 contact hours.

California Residents: This continuing nursing education activity was approved by the California Board of Registered Nursing. CME Outfitters, LLC’s provider number is CEP15510.

Interprofessional (IPCE) 1.0

This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education Credit for learning and change.

Physician Assistants (AAPA): 1.00

CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

ABIM MOC 1.0

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

UEMS-EACCME®

Through a mutual recognition agreement between the AMA and the UEMS-EACCME, European physicians completing an e-learning activity from a US-based ACCME-accredited CME provider can use AMA PRA Category 1 Credit™ toward their credit requirements. CME Outfitters is based in Radnor, Pennsylvania, USA. Please retain your certificate as proof of completion.

Disclosure Declaration

Dr. Kowdley reports the following financial relationships:

Consultant: 89bio, Inc.; Arbormed Pharmaceuticals; Boehringer Ingelheim; CymaBay Therapeutics Inc.; Genfit; Gilead Sciences, Inc.; GSK; HighTide Therapeutics, Inc.; Inipharm; Intercept Pharmaceuticals, Inc.; Ipsen Pharma; Madrigal Pharmaceuticals; Mirum; NGM Biopharmaceuticals; Novo Nordisk; Orphalan; Pfizer Inc.; and Zydus Pharmaceuticals, Inc.

Grants: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Research Support: 89bio, Inc.; Akero Therapeutics, Inc.; AstraZeneca; Boston Pharmaceuticals; Boehringer Ingelheim; Corcept Therapeutics, Inc.; Gilead Sciences, Inc.; GSK; Hanmi Pharmaceutical; Intercept Pharmaceuticals, Inc.; Inventiva; Janssen Pharmaceuticals, Inc.; Madrigal Pharmaceuticals; Mirum, NGM Biopharmaceuticals; Novo Nordisk; Pfizer Inc.; Pliant Therapeutics, Inc.; Terns Pharmaceuticals, Inc.; Viking Therapeutics; and Zydus Pharmaceuticals, Inc.

Speakers Bureau: AbbVie Inc.; Gilead Sciences, Inc.; Intercept Pharmaceuticals, Inc.; and Ipsen Pharma

Other financial or material support: Royalties: UpToDate

Dr. Gulamhusein reports the following financial relationships:

Advisory Board: Cymabay Therapeutics, Inc. and Gilead Sciences, Inc.

Consultant: Advanz Pharma

Grants: Calliditas Therapeutics; Cymabay Therapeutics, Inc.; Genkyotex Suisse SA; Gilead Sciences, Inc.; Intercept Pharmaceuticals, Inc.; and Novartis

Dr. Werner reports the following financial relationships:

Speakers Bureau: Madrigal Pharmaceuticals

The following individuals have no financial relationships to disclose:

Jeffrey Helfand, DO (Peer Reviewer)
Shirley Michelle Franks, MSN, APRN, FNP-BC (Peer Reviewer)
Thomas Mitchell, MSW (Planning Committee)
Warren Beckman (Planning Committee)
Scott J. Hershman, MD, FACEHP, CHCP (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)

Questions about this activity?

Call us at 877.CME.PROS (877.263.7767).

WC-089-120424-47

Diagnostic and Therapeutic Advances in Primary Biliary Cholangitis: Maximizing Opportunities to Improve Patient Care and Outcomes

Faculty

Statement of Need

Learning Objectives

Financial Support

Target Audience